Innate Pharma S.A. (NASDAQ:IPHA) Q4 2022 Earnings Call Transcript

Mondher Mahjoubi: Thank you, Yannis. Any offline question, additional offline questions?

Henry Wheeler: Not from this stage. Operator, over to you for any further questions on the line.

Operator: Yes. Your next question comes from the line of Jingming Chen with Evercore ISI. Your line is open.

Jingming Chen: Hi. This is Jingming on for Liisa. Thanks for taking our questions. So, we are just wondering for your first ANKET, the IPH6101 CD123, when shall we expect to see the Phase 1 data and what should we expect from the readout? Thank you.

Mondher Mahjoubi: Thank you for the question. As you know, this is a Sanofi asset. It’s a Sanofi trial, and we, of course, cannot speculate or communicate on their behalf. Sanofi is progressing well. And they mentioned in their full year results, early February that the program is progressing well. And of course we will wait for the data that they can provide the study, Phase 1 study started about 15 months ago, and we do not have any additional update to share with you at this .

Jingming Chen: Got it. Thank you.

Mondher Mahjoubi: Yannis — okay. Yannis, anything to add from your side?

Yannis Morel: No, nothing to add.

Mondher Mahjoubi: Okay. Thank you.

Operator: There are no further audio questions at this time.

Mondher Mahjoubi: Okay. So if there are no further question, I would like ladies and gentlemen, to thank you all for attending this call. And maybe, let me quickly remind you our key take homes and there are three. First of all, as you see, we stay focused on our strategic priorities to adventure lacutamab maximizing the NK platform and building strategic partnership. Number two, clearly we have important readouts from our proprietary and partnered portfolio programs that are expected over the next 24 months. And last but not least, we have a strong financial position as we are well funded into mid 2025. We’ll keep you posted, and thank you again for participating to this call. Bye-bye.

Operator: Ladies and gentlemen, thank you for participating. This concludes today’s conference call. You may now disconnect.